Table 2.

Univariable and multivariable analysis of clinicopathological parameters for tumour regression grade 3–4 in the retrospective cohort

	Univariable analysis		Multivariable analysis‡
	Odds ratio	P	Odds ratio	P
CD133 (low versus high)	15·24 (2·93, 280·48)	< 0·001	8·52 (1·38, 168·18)	0·018
COX‐2 (low versus high)	6·88 (2·41, 21·86)	< 0·001	5·83 (1·68, 23·39)	0·005
CD8+ TIL (high versus low)	4·34 (1·64, 12·04)	0·003	3·01 (0·93, 10·15)	0·066
Age (> 68 versus ≤ 68 years)*	1·71 (0·66, 4·39)	0·262
Sex (M versus F)	1·01 (0·41, 2·61)	0·973
Pretreatment cT category (cT3 versus cT4)	1·62 (0·20, 33·41)	0·668
Pretreatment cN category (cN0 versus cN1–2)	2·86 (1·16, 7·19)	0·023	2·16 (0·72, 6·58)	0·167
Pretreatment tumour size (≤ 52·6 versus > 52·6 mm)*	4·09 (1·25, 18·56)	0·018	2·37 (0·60, 11·99)	0·226
Distance to anal verge (≤ 40 versus > 40 mm)*	3·00 (1·27, 7·35)	0·012	2·23 (0·78, 6·70)	0·135
Tumour differentiation in pretreatment biopsy specimen (well/moderate versus poor, mucinous or signet)†	0·24 (0·03, 1·31)	0·100
Pretreatment CEA level (≤ 5·3 versus > 5·3 ng/ml)	1·64 (0·63, 4·68)	0·320
Pretreatment CA19‐9 level (≤ 37 versus > 37 units/ml)	1·23 (0·37, 4·86)	0·744

Values in parentheses are 95 per cent confidence intervals.

^*Cut‐off determined by receiver operating characteristic (ROC) curve analysis.

^†Well or moderately differentiated tubular adenocarcinoma versus moderately differentiated or mucinous tubular adenocarcinoma, or signet ring cell carcinoma. CD, cluster of differentiation; COX, cyclo‐oxygenase; TIL, tumour‐infiltrating lymphocyte; CEA, carcinoembryonic antigen; CA, carbohydrate antigen.

^‡Logistic multivariable analysis of variables with P < 0·050 in univariable analysis.